REG - Hikma Pharmaceutical - AGM Results

Hikma PharmaceuticalsAnnouncement

18/05/2018 13:05

RNS Number : 6033O
Hikma Pharmaceuticals Plc
18 May 2018
 

 
Hikma Pharmaceuticals PLC
Voting Results of 2018 Annual General Meeting
LONDON, 18 May 2018 - Hikma Pharmaceuticals PLC (the "Company") announces its Annual General Meeting ("AGM"), held at Sofitel St James, 6 Waterloo Place, London SW1Y 4AN on 18 May 2018 commenced at 10:00 am. All resolutions were duly passed by shareholders by way of a poll. Resolutions 1 to 17 were passed as ordinary resolutions and Resolutions 18 to 21 were passed as special resolutions.
As previously announced, Dr. Ronald Goode retired from the Board at the close of the AGM.
Copies of the resolutions dealing with special business passed at the AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at www.morningstar.co.uk/uk/nsm
The total number of votes cast on the poll for each resolution (the full text of the resolutions is detailed in the notice of the AGM dated 28 March 2018) is set out below. The number of Ordinary Shares in issue on 18 May 2018 was 240,940,604.




Resolution


Votes For


%


Votes Against


%


Total Cast


Withheld






1. To receive the 2017 report and accounts


196,394,230


99.96


72,200


0.04


196,466,430


245,708




2. To approve a final dividend of 23 cents per share


196,485,553


99.89


225,796


0.11


196,711,349


788




3. To re-appoint PricewaterhouseCoopers LLP as auditors


196,099,742


99.69


610,679


0.31


196,710,421


1,717




4.To authorise the Audit Committee to determine the auditors' remuneration


196,703,625


100.00


5,721


0.00


196,709,346


2,792




5. To elect Siggi Olafsson as a director


195,815,999


99.55


894,642


0.45


196,710,641


1,497




6. To re-elect Said Darwazah as a director


190,417,700


96.80


6,298,814


3.20


196,716,514


1,622




7. To re-elect Mazen Darwazah as a director


193,925,828


98.58


2,783,900


1.42


196,709,728


2,410




8. To re-elect Robert Pickering as a director


190,879,517


98.02


3,848,509


1.98


194,728,026


1,984,111




9.To re-elect Ali Al-Husry as a director


195,245,623


99.26


1,464,293


0.74


196,709,916


2,222




10. To re-elect Patrick Butler as a director


193,317,043


98.28


3,393,072


1.72


196,710,115


2,022




11. To re-elect Dr. Jochen Gann as a director


195,107,616


99.19


1,602,499


0.81


196,710,115


2,022




12. To re-elect John Castellani as a director


193,529,031


98.38


3,180,885


1.62


196,709,916


2,222




13. To re-elect Dr. Pamela Kirby as a director


190,289,183


96.74


6,421,682


3.26


196,710,865


1,272




14. To re-elect Nina Henderson as a director


192,848,157


98.04


3,862,508


1.96


196,710,665


1,472




15. To approve the remuneration report for the year ended 31 December 2017


169,750,519


86.36


26,815,358


13.64


196,565,877


146,261




16. To approve and adopt the 2018 Management Incentive Plan


195,620,834


99.45


1,088,481


0.55


196,709,315


2,822




17. Authority to allot shares


166,598,638


84.69


30,112,333


15.31


196,710,971


1,167




18. To dis-apply pre-emption rights for general purposes


196,660,802


99.97


50,469


0.03


196,711,271


867




19. To dis-apply pre-emption rights for an acquisition or other capital investment


195,530,359


99.40


1,179,711


0.60


196,710,070


2,067




20. To authorise the Company to purchase its own shares


195,989,881


99.68


621,703


0.32


196,611,584


100,553




21. To authorise the Company to hold general meetings on no less than 14 clear days' notice


187,831,722


95.49


8,878,028


4.51


196,709,750


2,388




 
Declaration of final dividend
The dividend of 23 cents per share will be paid on 24 May 2018 to shareholders on the register on 6 April 2018.  Shareholders who are not resident in Jordan have been given the option of receiving their dividend in Pounds Sterling.  The exchange rate in respect of this dividend will be $1.3521 to £1. The exchange rate for Jordanian Dinar is fixed to the US Dollar at circa 1JD to $1.41.
- ENDS -
Enquiries:
 




Hikma Pharmaceuticals PLC


 




Peter Speirs
Company Secretary
 


+44 20 7399 2670




Susan Ringdal
VP for Investor Relations and Strategy
 


+44 20 7399 2670
 




 
 
About Hikma
Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world.  For 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. We're a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner in the MENA region, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit www.hikma.com.
 
 
LEI: 549300BNS685UXH4JI75



This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGUWRURWRAVAAR